Meeting
2018 ASCO Annual Meeting
Randomized, open-label, phase Ⅱ trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma.
Authors
He Huang
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
He Huang , Xue Ying Li , Huang Ming Hong , Zhao Wang , Xiaojie Fang , Fangfang Li , Chen Peng , Quanguang Ren , Fushen Sha , Limei Zhang , Suxia Lin , Qing Liu , Tongyu Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7560)
DOI
10.1200/JCO.2018.36.15_suppl.7560
Abstract #
7560
Poster Bd #
197
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
First Author: Carrie Ho
Poster
2022 ASCO Annual Meeting
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.
First Author: Lorenzo Falchi
Poster
2023 ASCO Annual Meeting
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
First Author: Bei Hu
Poster
2023 ASCO Annual Meeting
Evaluation of outcomes between rituximab-abbs and reference product rituximab in adult patients with newly diagnosed diffuse large B-cell lymphoma in a non-inferiority study.
First Author: Vivian Nguyen